Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies.

Antibodies Cell transplantation HTT gene silencing Huntington disease Intrastriatal infusion Neurotrophic factors

Journal

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381

Informations de publication

Date de publication:
19 Sep 2024
Historique:
received: 25 06 2024
revised: 12 09 2024
accepted: 12 09 2024
medline: 21 9 2024
pubmed: 21 9 2024
entrez: 20 9 2024
Statut: aheadofprint

Résumé

Huntington disease (HD) is an autosomal dominant neurodegenerative disorder characterized by choreic movements, behavioral changes, and cognitive impairment. The pathogenesis of this process is a consequence of mutant protein toxicity in striatal and cortical neurons. Thus far, neurosurgical management of HD has largely been limited to symptomatic relief of motor symptoms using ablative and stimulation techniques. These interventions, however, do not modify the progressive course of the disease. More recently, disease-modifying experimental therapeutic strategies have emerged targeting intrastriatal infusion of neurotrophic factors, cell transplantation, HTT gene silencing, and delivery of intrabodies. Herein we review therapies requiring neurosurgical intervention, including those targeting symptom management and more recent disease-modifying agents, with a focus on safety, efficacy, and surgical considerations.

Identifiants

pubmed: 39304438
pii: S1878-7479(24)00139-9
doi: 10.1016/j.neurot.2024.e00452
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00452

Informations de copyright

Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shervin Rahimpour reports a relationship with Abbott that includes: consulting or advisory and speaking and lecture fees. Shervin Rahimpour reports a relationship with Boston Scientific Corporation that includes: consulting or advisory and speaking and lecture fees. Andres M. Lozano reports a relationship with Functional Neuromodulation that includes: board membership. Andres M. Lozano reports a relationship with Medtronic Inc that includes: consulting or advisory. Andres M. Lozano reports a relationship with Abbott that includes: consulting or advisory. Andres M. Lozano reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Andres M. Lozano reports a relationship with Insightec that includes: consulting or advisory. Andres M. Lozano reports a relationship with Focused Ultrasound Foundation that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Leo J Y Kim (LJY)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA.

Bornali Kundu (B)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA.

Paolo Moretti (P)

Department of Neurology, University of Utah, Salt Lake City, UT, USA; Department of Neurology, George E. Wahlen VA Medical Center, Salt Lake City, UT, USA.

Andres M Lozano (AM)

Division of Neurosurgery and Toronto Western Hospital Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Shervin Rahimpour (S)

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. Electronic address: neuropub@hsc.utah.edu.

Classifications MeSH